hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review

被引:69
作者
Nordh, Stina [1 ,2 ]
Ansari, Daniel [1 ,2 ]
Andersson, Roland [1 ,2 ]
机构
[1] Lund Univ, Dept Surg, SE-22185 Lund, Sweden
[2] Skane Univ Hosp, SE-22185 Lund, Sweden
关键词
Pancreatic cancer; Gemcitabine; hENT1; Predictive; Survival; NUCLEOSIDE TRANSPORTER 1; RANDOMIZED CONTROLLED-TRIAL; ADJUVANT CHEMOTHERAPY; SURGICAL RESECTION; DRUG TOXICITY; SURVIVAL; ADENOCARCINOMA; POLYMORPHISMS; THERAPY; ABSENCE;
D O I
10.3748/wjg.v20.i26.8482
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
High human equilibrative nucleoside transporter 1 (hENT1)-expression has shown a survival benefit in pancreatic cancer patients treated with gemcitabine in several studies. The aim of this systematic review was to summarize the results and try to assess the predictive value of hENT1 for determining gemcitabine outcome in pancreatic cancer. Relevant articles were obtained from PubMed, Embase and Cochrane databases. Studies evaluating hENT1-expression in pancreatic tumor cells from patients treated with gemcitabine were selected. Outcome measures were overall survival, disease-free survival (DFS), toxicity and response rate. The database searches identified 10 studies that met the eligibility criteria, and a total of 855 patients were included. Nine of 10 studies showed a statistically significant longer overall survival in univariate analyses in patients with high hENT1-expression compared to those with low expression. In the 7 studies that reported DFS as an outcome measure, 6 had statistically longer DFS in the high hENT1 groups. Both toxicity and response rate were reported in only 2 articles and it was therefore hard to draw any major conclusions. This review provides evidence that hENT1 is a predictive marker for pancreatic cancer patients treated with gemcitabine. Some limitations of the review have to be taken into consideration, the majority of the included studies had a retrospective design, and there was no standardized scoring protocol for hENT1-expression. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:8482 / 8490
页数:9
相关论文
共 31 条
[1]   Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration [J].
Altman, Douglas G. ;
McShane, Lisa M. ;
Sauerbrei, Willi ;
Taube, Sheila E. .
PLOS MEDICINE, 2012, 9 (05)
[2]   Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions [J].
Andersson, Roland ;
Aho, Ursula ;
Nilsson, Bo I. ;
Peters, Godefridus J. ;
Pastor-Anglada, Marcal ;
Rasch, Wenche ;
Sandvold, Marit L. .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (07) :782-786
[3]   Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies [J].
Andriulli, Angelo ;
Festa, Virginia ;
Botteri, Edoardo ;
Valvano, Maria R. ;
Koch, Maurizio ;
Bassi, Claudio ;
Maisonneuve, Patrick ;
Di Sebastiano, Pierluigi .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (05) :1644-1662
[4]   Pancreatic cancer - cost for overtreatment with gemcitabine [J].
Ansari, Daniel ;
Tingstedt, Bobby ;
Andersson, Roland .
ACTA ONCOLOGICA, 2013, 52 (06) :1146-1151
[5]   Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer [J].
Ashida, Reiko ;
Nakata, Bunzo ;
Shigekawa, Minoru ;
Mizuno, Nobumasa ;
Sawaki, Akira ;
Hirakawa, Kosei ;
Arakawa, Tetsuo ;
Yamao, Kenji .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2009, 28
[6]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[7]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[8]   Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer [J].
Farrell, James J. ;
Elsaleh, Hany ;
Garcia, Miguel ;
Lai, Raymond ;
Ammar, Ali ;
Regine, William F. ;
Abrams, Ross ;
Benson, A. Bowen ;
MacDonald, John ;
Cass, Carol E. ;
Dicker, Adam P. ;
Mackey, John R. .
GASTROENTEROLOGY, 2009, 136 (01) :187-195
[9]   Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy [J].
Fujita, Hayato ;
Ohuchida, Kenoki ;
Mizumoto, Kazuhiro ;
Itaba, Soichi ;
Ito, Tetsuhide ;
Nakata, Kohei ;
Yu, Jun ;
Kayashima, Tadashi ;
Souzaki, Ryota ;
Tajiri, Tatsuro ;
Manabe, Tatsuya ;
Ohtsuka, Takao ;
Tanaka, Masao .
NEOPLASIA, 2010, 12 (10) :807-U161
[10]  
García-Manteiga J, 2003, CLIN CANCER RES, V9, P5000